UroGen Pharma Ltd. announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team. In this role, David will be spearheading UroGen?s commercial strategy, including preparation for the potential launch of lead pipeline candidate UGN-102, if approved, and driving the continued growth and commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution. David Lin brings to UroGen a wealth of experience garnered from a distinguished career in the pharmaceutical industry.

Prior to joining UroGen, David held several key leadership positions at Bristol Myers Squibb, where he played pivotal roles in driving the success of various initiatives. Notably, as Head of U.S.Cell Therapy, David led the successful launch of two CAR T therapies, showcasing his expertise in bringing innovative therapies to market. Additionally, his tenure as Head of Worldwide Cardiovascular contributed significantly to the global cardiovascular franchise, including expansion through the MyoKardia acquisition.

Before his time at Bristol Myers Squibb, David served as Global Head of Surgery and Perioperative Care at The Medicines Company, demonstrating his diverse experience across different sectors of the healthcare industry. His career journey also includes various leadership roles at Johnson & Johnson, where he made impactful contributions to pharmaceuticals, medical devices, and consumer businesses. David is an alumnus of Cornell University, where he earned his Bachelor of Arts in Economics, and Duke University, where he completed his Master of Business Administration (MBA).

Beyond his professional endeavors, David is actively engaged in mentoring start-up businesses in life sciences as a member of the Canadian Technology Accelerator and serves as a Strategic Advisor to ChroniSense Medical, a clinical-stage medical technology company. Jeff Bova will be stepping down as Chief Commercial Officer on June 3 as he pursues new opportunities.